GRAIL Galleri Wins FDA Panel Support for Cancer Test
Sunnyvale, California, September 23, 2026 GRAIL, Inc. announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics...
Liquid Biopsy
Advertisement
Natera Reports Largest Lung Cancer MRD Study for Signatera
AUSTIN, Texas — September 18, 2026 Natera announced new data from the IASLC 2026 World Conference on Lung Cancer...
Caris Life Sciences Promotes Caris Detect for Cancer
Irving, Texas, U.S, September 8, 2026 Caris Life Sciences, an artificial intelligence and precision medicine company, has launched a...
Guardant Health Wins FDA Approval for Breast Cancer CDx
Palo Alto, California — September 4, 2026 Guardant Health announced that the U.S. Food and Drug Administration (FDA) has...
Cizzle Bio Study Supports CIZ1B for Early Lung Cancer
Dallas, Texas, September 1, 2026 Cizzle Bio, Inc. has announced the publication of a new peer-reviewed study providing additional...
Advertisements
bioAffinity Technologies Advances CyPath Lung for Cancer Surveillance
SAN ANTONIO, September 1, 2026 bioAffinity Technologies, Inc. is advancing the potential use of its noninvasive CyPath® Lung test...
Guardant Health Expands Shield CRC Screening Coverage
PALO ALTO, Calif., Sept. 1, 2026 Guardant Health announced that its Shield blood test for colorectal cancer (CRC) screening...
Natera Partners With Susan G. Komen to Advance Breast Cancer Awareness
Austin, Texas – August 28, 2026 Natera, Inc. announced a new national partnership with Susan G. Komen to accelerate...
Cerenome Secures HCSC Agreement, Expanding CNSide Coverage
Houston, USA — August 13, 2026 Cerenome, Inc. announced that its wholly owned subsidiary CNSide Diagnostics, LLC has signed...
Natera, Inc. and Kupando Therapeutics Launch Phase 1 Study to Monitor ctDNA in Advanced Skin Cancers
AUSTIN, Texas, August 12, 2026 Natera, Inc. announced a new collaboration with Kupando Therapeutics to support a Phase 1...
Advertisement
